To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 28 March to Question 141960, whether he can provide an estimated date for the availability of Evusheld on the NHS.
Answered on
24 May 2022
Evusheld was granted a conditional marketing authorisation by the Medicines and Healthcare products Regulatory Agency on 17 March 2022. However, the initial positive trial data on Evusheld was published prior to the emergence of the Omicron variant.
The UK Health Security Agency is currently testing the efficacy of Evusheld against the Omicron variant and the Department and National Health Service are identifying appropriate patient cohorts and approaches to the potential deployment of pre-exposure prophylaxis. There is no current estimated date for the availability of Evusheld in the NHS.